Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer

S Koppikar; A Oaknin; K Govind Babu; D Lorusso; S Gupta; L-Y Wu; W Rajabto; K Harano; S-H Hong; R A Malik; H Strebel; I M Aggarwal; C-H Lai; T Dejthevaporn; S Tangjitgamol; W F Cheng; W Y Chay; D Benavides; N M Hashim; Y W Moon; M Yunokawa; T D Anggraeni; W Wei; G Curigliano; A Maheshwari; U Mahantshetty; S Sheshadri; S Peters; T Yoshino; G Pentheroudakis

doi:10.1016/j.esmoop.2022.100774

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer

ESMO Open. 2023 Feb;8(1):100774. doi: 10.1016/j.esmoop.2022.100774. Epub 2023 Jan 23.

Authors

S Koppikar¹, A Oaknin², K Govind Babu³, D Lorusso⁴, S Gupta⁵, L-Y Wu⁶, W Rajabto⁷, K Harano⁸, S-H Hong⁹, R A Malik¹⁰, H Strebel¹¹, I M Aggarwal¹², C-H Lai¹³, T Dejthevaporn¹⁴, S Tangjitgamol¹⁵, W F Cheng¹⁶, W Y Chay¹⁷, D Benavides¹⁸, N M Hashim¹⁹, Y W Moon²⁰, M Yunokawa²¹, T D Anggraeni⁷, W Wei²², G Curigliano²³, A Maheshwari²⁴, U Mahantshetty²⁵, S Sheshadri²⁶, S Peters²⁷, T Yoshino²⁸, G Pentheroudakis²⁹

Affiliations

¹ Department of Medical Oncology, Lilavati Hospital and Research Centre, Mumbai, India; Department of Medical Oncology, Bombay Hospital Institute of Medical Sciences, Mumbai, India. Electronic address: [email protected].
² Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
³ Department of Medical Oncology, HCG Hospital and St. Johns Medical College, Bengaluru, India.
⁴ Department of Life Science and Public Health, Catholic University of Sacred Heart, Largo Agostino Gemelli, Rome; Department of Women and Child Health, Division of Gynaecologic Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
⁵ Department of Medical Oncology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India.
⁶ Department of Gynecologic Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
⁷ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Dr. Cipto Mangunkusumo General Hospital/Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia.
⁸ Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
⁹ Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
¹⁰ Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
¹¹ Division of Medical Oncology, Department of Internal Medicine, University of the Philippines, Philippine General Hospital, Manila, The Philippines.
¹² Department of Gynaecologic Oncology, KK Women's and Children's Hospital, Singapore, Singapore.
¹³ Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan, Taiwan.
¹⁴ Medical Oncology Unit, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
¹⁵ Department of Obstetrics and Gynecology, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand; Obstetrics and Gynecology Center, Medpark Hospital, Bangkok, Thailand.
¹⁶ Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan.
¹⁷ Division of Medical Oncology, National Cancer Centre, Singapore, Singapore.
¹⁸ Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, U.P. College of Medicine and Philippine General Hospital, Manila, The Philippines.
¹⁹ Oncology and Radiotherapy Department, KPJ Johor Specialist Hospital, Johor Bahru, Malaysia.
²⁰ Department of Hematology and Oncology, CHA Bundang Medical Center (CBMC), CHA University, Seongnam, Gyeonggi-do, Republic of Korea.
²¹ Department of Gynecology and Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan.
²² Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.
²³ European Institute of Oncology, IRCCS, Milano, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy.
²⁴ Department of Gynecologic Oncology, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India.
²⁵ Department of Radiation Oncology, Homi Bhabha Cancer Hospital and Research Hospital, Vishakhapatnam, India.
²⁶ Department of Pathology, Kidwai Memorial Institute of Oncology, Bengaluru, India.
²⁷ Oncology Department, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
²⁸ Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
²⁹ ESMO, Lugano, Switzerland.

Abstract

The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer was published in 2022. It was therefore decided, by both the ESMO and the Indian Society of Medical and Paediatric Oncology (ISMPO), to convene a virtual meeting in July 2022 to adapt the ESMO 2022 guidelines to take into account the variations in the management of endometrial cancer in Asia. These guidelines represent the consensus opinion of a panel of Asian experts representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). Voting was based on scientific evidence and was conducted independently of the current treatment practices and treatment access constraints in the different Asian countries, which were discussed when appropriate. The aim of this guideline manuscript is to provide guidance for the optimisation and harmonisation of the management of patients with endometrial cancer across the different regions of Asia, drawing on the evidence provided by Western and Asian trials whilst respecting the variations in clinical presentation, diagnostic practices including molecular profiling and disparities in access to therapeutic options, including drug approvals and reimbursement strategies.

Keywords: ESMO; Pan-Asian; endometrial cancer; guidelines; treatment.

Publication types

Practice Guideline

MeSH terms

Asia
Child
Endometrial Neoplasms* / diagnosis
Female
Humans
Medical Oncology
Societies, Medical*